Last week, readers were most interested in a story about how priorities for the lab industry could play out depending on election results.

UK-based Cizzle Biotechnology signed the licensing agreement with its US-based partner, Cizzle Bio, for the commercialization of early cancer detection tests.

Last week, readers were most interested in a story about how priorities for the lab industry could play out depending on election results.

The automated real-time PCR-based test detects DNA from the virus that causes mpox using a dual-target approach and runs on Roche's high-throughput Cobas 6800/8800 systems. The EUL process is intended ...

The EU has awarded the researchers €188,000 to support the project through September 2026, by which time they hope to have a validated prototype ready.

Endometriosis is associated with debilitating pain and increased risk of cancer and autoimmune diseases, yet diagnosis remains out of reach for many patients.

In an open letter, the organization called on Danaher and its subsidiary Cepheid to further lower the price of its Xpert MTB/RIF Ultra tuberculosis test.

Aspira can now offer the test, intended for assessing ovarian cancer risk in women with an adnexal mass, to patients in New York state.

The assay uses amplification-refractory mutation system (ARMS) technology and genetic analyzers to detect the 50 most common CF mutations in European ancestry populations.

The assay evaluates a patient's tumor immune profile against Cofactor's high-dimensional RNA-based Health Expression Models to predict a patient's therapy response.

Hong Kong-based Prenetics, which had a 50 percent stake in Insighta, sold some of its secondary shares and will now hold a 35 percent stake in the company.